Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US5925351A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 21, 1995 |
| Grant date | Jul 20, 1999 |
| Priority date | — |
| Expiry date | Jul 21, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to compositions and methods comprising "lymphotoxin-.beta. receptor blocking agents", which block lymphotoxin-.beta. receptor signalling. Lymphotoxin-.beta. receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-.beta. receptor extracellular domain that act as lymphotoxin-.beta. receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-.beta. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-.beta. receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-.beta. receptor signalling is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.